Conversely, antagomir-17-5p treatment may be beneficial in MYCN-amplified neuroblastoma, also in view of evidence suggesting that systemic antagomir treatment is not coupled with significant toxicity[34], [48]. This evidence concerns the gene MYCN and neuroblastoma.